Qixiang Guo

发表

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database

Lihong Liu, Yuwei Liu, J. Lyu, 2021, Frontiers in Pharmacology.

The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis

S. Chow, Yue Zhou, Xingxian Luo, 2022, The Lancet regional health. Western Pacific.

Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.

Lihong Liu, Jiwen You, Shihao Wang, 2021, Gynecologic oncology.

Lenvatinib and osteonecrosis of the jaw: A pharmacovigilance study.

Lihong Liu, Zhuo Ma, Wenchao Lu, 2021, European journal of cancer.

Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System.

Lihong Liu, Zhuo Ma, Ximu Sun, 2021, European journal of cancer.

Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis

Z. Gou, Jiannan Yao, Wenchao Lu, 2023, Frontiers in Pharmacology.

Evaluation of clinical trial designs for novel anticancer drugs in China: a cohort study of drugs approved between 2015 and 2021.

S. Chow, Xingxian Luo, Lin Huang, 2023, Drug discovery today.

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022

S. Chow, Jingwen Liu, Xingxian Luo, 2023, EClinicalMedicine.

Anti-angiogenic agent-associated adrenal insufficiency in immune checkpoint inhibitors-treated patients.

Lihong Liu, Wenchao Lu, Ximu Sun, 2021, European journal of cancer.